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Computerized tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) and the hybrid modality of
PET/CT are sensitive and reliable tools for detection and staging of head and neck cancers. This article describes the role of PET/CT in initial
staging of head and neck squamous cell carcinoma, the utility of CT/MR perfusion imaging in qualitative analysis of tumor tissue, and the
usefulness of diffusion weighted MR and dynamic contrast-enhanced MR imaging in head and neck oncological imaging.
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Diagnostic imaging has come a long way from 1895 when Conrad
Roentgen discovered X-rays. Conventional radiography and ancillary
techniques like fluoroscopy and tomography had a relatively minor
role in evaluation of neoplasms of the head and neck unless it
encroached into the aero-digestive tract. Computerized tomography
(CT) was introduced in the 1970s and revolutionized body imaging. It
is inexpensive, fast, and ubiquitous in most medical centers. CT is quite
good at delineating tumor extent and nodal disease. In squamous cell
carcinoma, CT helped in tumor staging, which dictated patient manage-
ment and related to prognosis [1]. Subsequently, helical multi-detector
computerized tomography (MDCT) with 16 and now 64 detector rings
has rapidly become the new industry standard in CT imaging.
Magnetic resonance imaging (MRI) in the 1980s was a quantum
jump in diagnostic imaging of the human body, including imaging of
head and neck pathologies. Some of earliest investigations in head and
neck imaging with MRI highlighted the ability of MRI to differentiate
neoplastic from inflammatory lesions. MRI provides essential infor-
mation about the deep extension of clinically detected masses and also
delineates additional clinically unsuspected lesions [2]. It has added
value for detection of soft tissue extent, marrow involvement, and
perineural spread [3]. The excellent tissue characterization and
multiplanar imaging capability of MR imaging results in more
accurate diagnosis of neoplastic and benign processes [4,5].
However, early investigators credited MR imaging with greater
precision in head and neck imaging than was warranted [6].
Conventional MR imaging did not have the last word in histological
specificity, early detection of primary malignancy and differentiat-
ing neoplastic from inflammatory lymph nodes. In spite of early
enthusiasm, MR imaging did not eliminate the need for biopsies or
aspirations of lesions. Spin echo imaging is still the mainstay of MR
imaging, but now various new techniques hold promise for the future of
head and neck imaging.
Positron emission tomography (PET) has been utilized since the
1970s for clinical imaging. PET scanning with 18fluorodeoxyglucose
(18FDG) can be used for staging and evaluation of recurrence for
primary head and neck tumors. The principle for PET is based on the
metabolism of the neoplasm, primary or recurrent, and is more
sensitive than CT or MRI for T1-staged lesions [7]. The most recent
innovation in PET systems is the hybrid PET/CT scanners. Integration
of PET with CT scan in 2000 was a great leap forward and enhanced
the clinical information from PET. Today all commercial PET scanners
are sold as PET/CT.
Various advanced techniques are utilized for answering some of the
unresolved issues from conventional CT, MRI and PET.
DIFFUSION WEIGHTED MAGNETIC
RESONANCE IMAGING
Diffusion weighted imaging (DWI) with magnetic resonance
relies upon the relative diffusivity of water protons within tissue. This
technique is based on the amount of random (Brownian) motion that
water protons undergo. During such an MRI examination, at least
two short echo-planar MRI pulse sequences are applied to generate
diffusion weighted images (DWI). However, some intrinsic T2
weighted information is contained in such images. Thus arithmetic
processing is performed between the sets to generate apparent
diffusion coefficient (ADC) maps, eliminating contributions from
T2 signal changes. In normal tissue or in areas exhibiting vasogenic
edema, the motion of water molecules is not limited and no restricted
diffusion should be noted. In tissues with cytotoxic edema or in highly
cellular regions, however, there is diffusion restriction, which can be
measured both qualitatively and quantitatively. This technique has
proven quite useful for brain imaging in differentiating between
infarcted tissue and other pathological processes [8]. Early studies have
also demonstrated that head and neck squamous cell cancers, likely due
to their high cellular content, can demonstrate restricted diffusion [9].
While conventional imaging techniques are often adequate for
demonstrating initial tumor extent, post-treatment changes can be
difficult to delineate from small volumes of tumor recurrence, as both
may enhance in a similar fashion. Diffusion weighted MRI can aid
in these situations. Inflammatory or post-treatment tissue does not
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demonstrate restricted diffusion, likely due to relative low cellularity.
Recurrent or residual disease, however, contains regions of increased
cellularity and thus should demonstrate restricted diffusion (Fig. 1)
[10]. Recent studies have maintained that such imaging can be a useful
adjunct in assessing post-treatment disease and may aid in diagnosis,
particularly with regard to tissue sampling [11]. Diffusion weighted
imaging of the orophayrynx can easily be performed at the time of
MR conventional imaging and adds approximately only 1–2 min of
additional time to the examination. High sensitivities and specificities
better than CT or conventional MRI are also reported in staging of neck
lymph nodes in squamous cell carcinoma [12,13]. Whole body DWI at
high b-values with ADC mapping is technically feasible and improves
assessment of metastatic spread in routine MR examinations
[14]. However, technical standardization is still not achieved; results
obtained depend on selection of b-values. Magnetic field inhomo-
geneity and suboptimal placement of receiver coils can have a negative
impact on image quality [10]. Interpretation of DWI in the head and
neck requires training and experience and more research is still needed
in this field.
PERFUSION IMAGING
Perfusion imaging, whether performed with CT or MRI, evaluates
dynamic microscopic blood flow changes through a region of interest.
Changes in tissue signal intensity (MRI) or attenuation (CT) are
measured during a dynamic contrast infusion. Blood flow, blood
volume, and transit time parameters of tissue regions can be then
generated, either on the CT scanner or on a separate workstation with
commercially available software. Perfusion characteristics of tissue
demonstrate changes in blood flow or volume of the interrogated
areas depending on the underlying pathologic processes. This
technique has been previously studied in characterizing brain ischemia,
particularly in identifying infarcted tissue versus tissue at risk [15].
Neoplastic tissue also demonstrates changes in perfusion character-
istics. Early studies have shown that oropharyngeal tumor tissue
demonstrates increased blood volume and blood flow with decreased
transit times in comparison to normal tissue [16].
Generally, these findings may not add substantial additional
information regarding tumor extent at the time of diagnosis. However,
such imaging may be of benefit in qualitative analysis of tumor
tissue. Specifically, additional recent studies have demonstrated that
squamous cell carcinomas of the upper aerodigestive tract with
increased blood volume/flow are more chemosensitive than other
lesions with relative decreased perfusion parameters (Fig. 2). This is
likely due to relative increased oxygenation and metabolism of such
lesions [17]. Such perfusion techniques could be particularly useful
in determining which patients would benefit from such medical
treatment, as opposed to surgical therapies which may not always
preserve organ function.
An additional area of interest is in regard to tumor recurrence or
regression. Again, conventional MRI or CT may simply demonstrate
increased contrast enhancement within the treated neck. Morphologic
changes in tissue appearance (such as increase in size or nodularity)
may not be well demonstrated on early post-treatment conventional
imaging. However, recent studies have concluded that for recurrent
oral cavity and oropharyngeal carcinomas, perfusion parameters are
altered. Specifically, blood volume and blood flow within recurrent
tumor tissue are elevated in comparison to therapy-altered tissue, with
corresponding decreases in transit time [18]. Perfusion imaging, like
diffusion imaging, adds little time to either conventional MRI or CT
examinations and can also be obtained noninvasively [19]. Blood flow,
volume, and transit time maps can be generated either on the unit or on
a separate workstation.
PET CT FOR DIAGNOSIS AND INITIAL STAGING
The clinical usefulness and role of FDG-PET CT for detection of
lymph node involvement and recurrences in patients with head and
neck cancer is very well-established [20]. It has been found to be
superior to conventional imaging work-ups in the evaluation of patients
with head and neck malignancies [21]. FDG PET is also found to be
more accurate than CT/MRI imaging in oral cavity cancer [22].
However, potential clinical applications include pretreatment staging,
treatment monitoring and evaluation of the previously treated patients
[23]. The current practice is not in favor of utilizing CT-PET for
staging of all newly diagnosed squamous cell carcinomas. However,
PET can detect metastatic cervical lymph nodes, which may be
clinically occult and may not be detected by CT or MR imaging [24]. It
can also detect primary head and neck squamous cell carcinomas
greater than 1 cm in size.
PET-CT may be performed in squamous cell carcinoma to evaluate
for possible occult distant metastases to the lungs or bones [25]. The
presence of pulmonary metastases upstages a patient from M0 to M1
and alters the treatment regimen (Fig. 3). Routine imaging work-up for
the patient with pulmonary squamous cell carcinoma includes
conventional radiography of the chest at most institutions. Chest CT
is performed in patients with advanced stage disease. A solitary nodule
on CT scan may represent a metastasis or a granuloma. PET would be
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Fig. 1. Large posterior oropharyngeal wall squamous cell carcinoma demonstrates increased DWI (A) and decreased ADC (B) signal intensity
at presentation. Post-therapy, the lesion has decreased greatly in size (C).
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helpful in this evaluation as an FDG-positive nodule would likely be
metastatic and may require biopsy. An FDG-negative nodule may
likely indicate a granuloma. Various studies have evaluated the diag-
nostic accuracy of PET-FDG for detecting metastatic cervical lymph
nodes. It has a high negative predictive value (NPV) of approximately
90%, which is more than any other imaging modality. With future
technological advances, PET-CT is likely to have high resolution CT
imaging. This is likely to increase the diagnostic accuracy of combined
PET-CT, which may have greater impact on management of N0 [26]
disease.
The ability of PET-CT to detect unknown primary tumors of the
upper arodigestive tract is well-documented [27–29]. PET can detect
squamous cell carcinoma in 30–50% of patients presenting with
an unknown primary tumor. PET-CT is generally performed after
confirming the presence of metastatic squamous cell carcinoma. It is
usually performed before endoscopic biopsies to improve the tissue
yield. This diagnostic yield can increase with PET-CT because as it
improves the anatomic localization of areas of abnormal FDG uptake
[30,31].
PET-CT can also be potentially utilized for determining response to
chemotherapy and/or radiation. Comparison of pretreatment standard
uptake values (SUVs) to SUVs 2 weeks into treatment can allow
measurement of the speed of response and also the sensitivity of the
tumor to the treatment technique [32]. Poorly responsive tumors can
then be treated to higher effective tumor doses of radiation, or surgery
can be performed. Initial results suggest that PET-CT can be used to
assist in defining primary site and nodal tumor targets for radiation
therapy approaches. PET-CT is a useful adjuvant to clinical staging of




Enhancement of a body tissue depends on vascularity, capillary
permeability, renal clearance and volume and composition of
extracellular fluid [33,34]. After intravenous administration of a bolus
Journal of Surgical Oncology
Fig. 2. Blood volume map of the same patient as in Figure 1A–C demonstrates increased perfusion values of the lesion (circled) in comparison
to the adjacent tissues at presentation. [Color figure can be viewed in the online issue, available at www.interscience.wiley.com.]
Fig. 3. T3N2 pyriform sinus carcinoma. A: Axial PET-CT demonstrates avid FDG uptake in a right pyriform sinus carcinoma and a metastatic
right cervical lymph node. B: PET-CT of the chest shows a mediastinal mass with focal increased uptake. This was not detected on conventional
radiography of the chest. [Color figure can be viewed in the online issue, available at www.interscience.wiley.com.]
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of paramagnetic contrast agent, it rapidly passes in to extravascular
space except in brain, retina and testes where specific vascular barriers
prevent it. This passage depends on the flow of the blood, and the
surface area and thickness of micro vessels. In case of malignant
tumors and lymph nodes, the vascular permeability is greater than
inflow of blood and hence blood perfusion is dominant factor for
contrast enhancement [35]. The tumor microenvironment has
increased microvascular permeability and diameter, increased flow
and blood volume of microvasculature, increased tissue oxygenation
and metabolism, and many times increased fractional volume of
extravascular extracellular space [36]. All these parameters result in
the rapid onset of contrast enhancement, which may taper off rapidly
or may persist depending on tissue parameters (Fig. 4A,B). After
passing in to extracellular spaces, the contrast begins to diffuse into
tissue compartments farther than vasculature and eventually over
several minutes to hours, diffuses back into vasculature. In areas of
fibrosis and necrosis, the elimination of contrast is slower due to
slower exchange rates and hence they exhibit persistent delayed
contrast characteristics [37]. Tissue perfusion and blood volume
can be evaluated and measured with a designed protocol of T1- and
sometimes T2*-weighted images. Field inhomogeneities caused by
intravascular contrast media can be quantified by the T2*-weighted
method [38] while shortening of T1 relaxation times can be quantified
by T1-weighted sequences.
Dynamic contrast-enhanced MR imaging has been utilized to
study head and neck cancers [39–43]. Escott et al. [39] did not analyze
signal intensity versus time curves, but noted that dynamic gradient-
echo MR imaging was superior to conventional contrast-enhanced
spin-echo imaging in delineating margins and extent of tumor. Guckel
et al. [42] used dynamic contrast-enhanced MR imaging to evaluate
signal intensity versus time for squamous cell carcinoma of the oral
cavity and oropharynx and found that the time/intensity curves of
the tumors could be divided into two groups, one showing a rapid
enhancement pattern with an early peak and then a continuous decrease
and one showing a slower but continuous increase that then gradually
decreased. Baba et al. [41] found that dynamic MR imaging was useful
in distinguishing persistent head and neck tumor from post -radiation
fibrosis by showing early enhancement in residual tumor. Hoskin
et al. [43] also assessed dynamic contrast-enhanced MR imaging as a
predictor of response to accelerated radiation therapy for advanced
head and neck cancer. They found that tumors with diminished tumor
perfusion at the end of radiotherapy are more likely to respond to
radiation and those that show greater post-contrast enhancement after
accelerated radiotherapy are likely to fail locally and suggested that
tumor blood flow is an important parameter in predicting the
outcome from radiotherapy. However, it was felt that dynamic
contrast-enhanced imaging has a very limited and non-significant role
and that unless invasion or T2 hypointensity was present, dynamic MR
imaging has a relatively small role to play in evaluating nonvascular
masses of head and neck [44].
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